A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors.

CBP-1018 - Coherent Biopharma

https://meetings.asco.org/abstracts-presentations/225054

Kaiwen Li; Junyan Wu; Suiwen Ye; Yanqiong Liu; Hao Huang; Fan Fan; Yiming Lai; Suili Zhuang; Liyan Zhou; Robert Huang; Yan Teng; Xiaoyan Chai; Yehui Shi; Hai Huang

Apr 27, 2023